JP2015533822A5 - - Google Patents

Download PDF

Info

Publication number
JP2015533822A5
JP2015533822A5 JP2015534689A JP2015534689A JP2015533822A5 JP 2015533822 A5 JP2015533822 A5 JP 2015533822A5 JP 2015534689 A JP2015534689 A JP 2015534689A JP 2015534689 A JP2015534689 A JP 2015534689A JP 2015533822 A5 JP2015533822 A5 JP 2015533822A5
Authority
JP
Japan
Prior art keywords
pyridin
pyrido
pyrimidin
cyclopropyl
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015534689A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015533822A (ja
JP6535430B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/062085 external-priority patent/WO2014052699A1/en
Publication of JP2015533822A publication Critical patent/JP2015533822A/ja
Publication of JP2015533822A5 publication Critical patent/JP2015533822A5/ja
Application granted granted Critical
Publication of JP6535430B2 publication Critical patent/JP6535430B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015534689A 2012-09-28 2013-09-27 非定型プロテインキナーゼcのアザキナゾリン阻害薬 Active JP6535430B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261707340P 2012-09-28 2012-09-28
US61/707,340 2012-09-28
US201361781364P 2013-03-14 2013-03-14
US61/781,364 2013-03-14
PCT/US2013/062085 WO2014052699A1 (en) 2012-09-28 2013-09-27 Azaquinazoline inhibitors of atypical protein kinase c

Publications (3)

Publication Number Publication Date
JP2015533822A JP2015533822A (ja) 2015-11-26
JP2015533822A5 true JP2015533822A5 (enExample) 2017-06-22
JP6535430B2 JP6535430B2 (ja) 2019-06-26

Family

ID=49326872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015534689A Active JP6535430B2 (ja) 2012-09-28 2013-09-27 非定型プロテインキナーゼcのアザキナゾリン阻害薬

Country Status (18)

Country Link
US (2) US9914730B2 (enExample)
EP (1) EP2900666B1 (enExample)
JP (1) JP6535430B2 (enExample)
KR (1) KR102215272B1 (enExample)
CN (1) CN105102456B (enExample)
AU (1) AU2013323360B2 (enExample)
BR (1) BR112015007061B1 (enExample)
CA (1) CA2886495C (enExample)
CL (1) CL2015000781A1 (enExample)
EA (1) EA030253B1 (enExample)
IL (1) IL237918B (enExample)
MX (1) MX372736B (enExample)
NZ (1) NZ706857A (enExample)
PH (1) PH12015500689A1 (enExample)
SG (1) SG11201502301YA (enExample)
TW (1) TWI663165B (enExample)
WO (1) WO2014052699A1 (enExample)
ZA (1) ZA201502783B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6535430B2 (ja) * 2012-09-28 2019-06-26 イグニタ、インク. 非定型プロテインキナーゼcのアザキナゾリン阻害薬
WO2014100501A1 (en) 2012-12-20 2014-06-26 Sanford-Burnham Medical Research Institute Small molecule agonists of neurotensin receptor 1
EA029052B1 (ru) 2013-03-14 2018-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
ES3069593T3 (en) 2013-08-23 2026-06-09 Neupharma Inc Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer
WO2015143376A1 (en) * 2014-03-21 2015-09-24 Nivalis Therapeutics, Inc. Novel compounds for the treatment of cystic fibrosis
TWI675836B (zh) 2014-03-25 2019-11-01 美商伊格尼塔公司 非典型蛋白質激酶c之氮雜喹唑啉抑制劑
WO2015200534A2 (en) * 2014-06-25 2015-12-30 Sanford-Burnham Medical Research Institute Small molecule agonists of neurotensin receptor 1
WO2016004305A2 (en) 2014-07-02 2016-01-07 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CA2960101C (en) * 2014-09-05 2024-05-21 Allosteros Therapeutics, Inc. Substituted carboline derivative and compositions thereof useful as camkii inhibitors
HUE047208T2 (hu) 2014-09-12 2020-04-28 Boehringer Ingelheim Int A katepszin-C spirociklikus inhibitorai
CN107001358A (zh) * 2014-10-29 2017-08-01 东亚St株式会社 调节组蛋白赖氨酸脱甲基酶(kdm)催化活性的新型吡啶并嘧啶酮化合物
CN105288512A (zh) * 2015-12-08 2016-02-03 李野林 一种治疗肥胖症的中药组合物
SG11201809559UA (en) 2016-06-13 2018-12-28 Glaxosmithkline Ip Dev Ltd Substituted pyridines as inhibitors of dnmt1
CN109843858B (zh) * 2016-08-15 2023-05-05 润新生物公司 某些化学实体、组合物及方法
AU2017312970B2 (en) * 2016-08-16 2021-08-12 Merck Patent Gmbh 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
JOP20190257A1 (ar) * 2017-04-28 2019-10-28 Novartis Ag مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
WO2018203219A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
WO2019000683A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
JP7311228B2 (ja) 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Rho-関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
US10329282B2 (en) 2017-06-30 2019-06-25 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
DK3827005T3 (da) * 2018-07-25 2022-09-19 Faes Farma Sa Pyridopyrimidiner som histamin H4-receptorhæmmere
EP3831823A4 (en) * 2018-08-01 2022-04-27 Shanghai Ennovabio Pharmaceuticals Co., Ltd. PREPARATION AND USE OF AN AROMATIC COMPOUND WITH IMMUNEGULATORY FUNCTION
CN111100063B (zh) * 2018-10-25 2022-05-17 南京药石科技股份有限公司 一种合成2-氟甲基取代的吡咯烷、哌啶以及哌嗪衍生物的制备方法
US20220143028A1 (en) * 2019-03-28 2022-05-12 Cancer Research Technology Ltd Inhibitors of atypical protein kinase c and their use in treating hedgehog pathway-dependent cancers
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
JP7688690B2 (ja) 2020-07-28 2025-06-04 スーチュアン・コールン-バイオテック・バイオファーマシューティカル・カンパニー・リミテッド ピリミジン系化合物の塩、結晶形およびその調製方法
CN116120243B (zh) * 2021-11-15 2025-07-29 都创(上海)医药科技股份有限公司 aPKC抑制剂化合物中间体片段及其制备方法和应用
CN114349711B (zh) * 2022-02-28 2023-08-15 四川依维欣医药科技有限公司 一种(R)-1-Boc-3-羟甲基哌嗪的合成方法
CN117088898B (zh) * 2022-05-13 2026-02-06 中国药科大学 稠环嘧啶类化合物及其制备方法、药物组合物和应用
US20260209221A1 (en) * 2022-12-13 2026-07-23 Windtree Therapeutics, Inc. Solid forms of {5-cyclopropyl-2-[2-(3,6-difluoro¬pyridin-2-ylamino)-pyridin-4-yl]-pyrido[3,4-d]pyrimidin-4-yl }-( (s)-3,3-dimethyl-piperidin-4-yl)-amine
CN117343005A (zh) * 2023-10-08 2024-01-05 上海泰坦科技股份有限公司 一种异烟酸衍生物的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4936700A (enExample) 1972-08-16 1974-04-05
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
JP2002080423A (ja) * 2000-09-06 2002-03-19 Daikin Ind Ltd トリフルオロ酢酸エチルの合成方法
AU2001290912A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4895806B2 (ja) * 2003-04-09 2012-03-14 エクセリクシス, インク. Tie−2モジュレータと使用方法
US20050038047A1 (en) * 2003-08-14 2005-02-17 Edwards Paul John Azaquinazoline derivatives
US7582631B2 (en) * 2004-01-14 2009-09-01 Amgen Inc. Substituted heterocyclic compounds and methods of use
MX2007010401A (es) * 2005-02-25 2008-02-19 Kudos Pharm Ltd Derivados de 2,4-diamino-piridopirimidina y su uso como inhbidores de mtor.
JP5227321B2 (ja) * 2006-08-23 2013-07-03 クドス ファーマシューティカルズ リミテッド Mtor阻害剤としての2−メチルモルホリンピリド−、ピラゾ−及びピリミド−ピリミジン誘導体
KR20090052385A (ko) * 2006-09-08 2009-05-25 화이자 프로덕츠 인크. 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온의합성
AU2010289321A1 (en) * 2009-09-04 2012-04-05 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
JP6535430B2 (ja) * 2012-09-28 2019-06-26 イグニタ、インク. 非定型プロテインキナーゼcのアザキナゾリン阻害薬
AU2014249233A1 (en) * 2013-03-13 2015-09-24 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
USRE49687E1 (en) * 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
BR112018012707A2 (pt) * 2015-12-22 2019-01-29 Vitae Pharmaceuticals Inc inibidores da interação de menin-mll

Similar Documents

Publication Publication Date Title
AU2013323360B2 (en) Azaquinazoline inhibitors of atypical protein kinase C
AU2019240299B2 (en) SHP2 phosphatase inhibitors and methods of use thereof
JP6336665B2 (ja) Fgfr阻害剤としての置換三環式化合物
AU2023382606A1 (en) Macrocyclic kras inhibitors and methods of use
EP2558468B1 (en) 5, 7-substituted-imidazo [1,2-c] pyrimidines as inhibitors of jak kinases
JP2024532734A (ja) 複素環式化合物及び使用方法
CN117651700A (zh) 2-氨基苯并噻唑化合物及使用方法
RU2473549C2 (ru) Пиримидиновые соединения, композиции и способы применения
KR101812357B1 (ko) Cdk4/6의 억제제로서의 피롤로피리미딘 화합물
JP2017518326A5 (enExample)
HRP20160649T1 (hr) Novi derivati tienopirimidina, postupci za njihovo pripremanje i njihova terapeutska uporaba
JP2015521600A5 (enExample)
JP2016504363A5 (enExample)
CA2687035A1 (en) Amino-heterocyclic compounds
HRP20151442T1 (hr) Spojevi heteroaril piridona i aza-piridona kao inhibitori btk-djelovanja
JP2011511034A5 (enExample)
JP2015537010A5 (enExample)
RU2015122895A (ru) Пуриновые ингибиторы человеческой фосфатидилинозит 3-киназы дельта
JP2017505327A5 (enExample)
JP2015504057A5 (enExample)
US20110152243A1 (en) Novel thienopyrrole compounds
JP2013512282A (ja) 新規三環式化合物
WO2025194057A1 (en) Macrocyclic compounds as modulators of kras and uses thereof
JP2021504380A5 (enExample)
WO2025230862A1 (en) Macrocyclic amino compounds as modulators of kras and uses therof